Transdermal fentanyl treatment in opioid-naïve cancer patients

  1. Gonzalez Barón, Manuel
  2. Ordóñez Gallego, Amalio
  3. Feliu Batlle, Jaime
  4. Espinosa Arranz, E.
  5. Castro Carpeño, Javier de
  6. Zamora Auñon, P.
  7. Martínez, Beatriz
  8. Casado Sáenz, Enrique
Journal:
Revista de oncología: Publicación oficial de la Federación de Sociedades Españolas de Oncología y del Instituto Nacional de Cancerología de México

ISSN: 1575-3018

Year of publication: 2003

Volume: 5

Issue: 3

Pages: 162-165

Type: Article

DOI: 10.1007/BF02712851 DIALNET GOOGLE SCHOLAR

More publications in: Revista de oncología: Publicación oficial de la Federación de Sociedades Españolas de Oncología y del Instituto Nacional de Cancerología de México

Abstract

To reach faster pain control in cancer patients we have designed an observational study to evaluate the effectiveness and safety of using different initial doses of transdermal fentanyl (fentanyl-TTS) based on initial pain intensity in opioid-naïve cancer patients. Initial doses of fentanyl-TTS were decided according to the baseline visual analogue scale (VAS): 25 µg/h if VAS ¿ 6 (24 patients), 50 µg/h if VAS > 6 (26 patients). Vas records at day 4 were <3 in 79% and 80% of the patients, for the lower and higher dose groups, respectively. Side effects (constipation, nausea, drowsiness) were minor and occurred in a small percentage of patients. Further studies are needed to confirm these results.

Data source: Dialnet